Recent Development of Immunotherapy for Treating Glioblastoma With a Focus on CAR-T Cells
Authors:
Open Access
- 1 January 2025
- journal article
- Published by Discovery Medicine in Discovery Medicine
- Vol. 37 (199) , 1423-1433
Abstract
Glioblastoma remains one of the most aggressive and treatment-resistant brain tumors, with current standard-of-care therapies offering limited survival benefits. Immunotherapy has emerged as a promising avenue to enhance anti-tumor immunity, with chimeric antigen receptor T (CAR-T) cell therapy gaining significant attention. While CAR-T therapies have demonstrated remarkable success in hematologic malignancies, their application in glioblastoma faces several challenges, including tumor heterogeneity, an immunosuppressive tumor microenvironment, limited blood-brain barrier penetration, T-cell exhaustion, and potential neurotoxicity. This review explores recent advancements in CAR-T therapy for glioblastoma, focusing on key tumor-associated antigens and innovative strategies to overcome treatment barriers. These include multi-antigen targeting, checkpoint inhibition, locoregional CAR-T delivery, synNotch, personalized CAR-T systems, and combination approaches with oncolytic viruses. We also discuss future directions for optimizing efficacy and safety. As the field advances, integrating synthetic biology and personalized antigen selection may further refine CAR-T therapy, offering renewed hope for glioblastoma patients.Keywords
This publication has 81 references indexed in Scilit:
- CAR T-cells for acute leukemias in children: current status, challenges, and future directionsCancer and Metastasis Reviews, 2025
- Identification and characterisation of novel CAR‐T cells to target IL13Rα2 positive human glioma in vitro and in vivoClinical and Translational Medicine, 2024
- Human gamma-delta (γδ) T cell therapy for glioblastoma: A novel alternative to overcome challenges of adoptive immune cell therapyCancer Letters, 2023
- Glioblastoma and Other Primary Brain Malignancies in AdultsJAMA, 2023
- A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral HeterogeneityCell, 2019
- Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid TumorsCancer Cell, 2019
- B7-H3 as a Novel CAR-T Therapeutic Target for GlioblastomaMolecular Therapy-Oncolytics, 2019
- Targeting EGFRvIII for glioblastoma multiformeCancer Letters, 2017
- Prognostic significance of CD147 in patients with glioblastomaJournal of Neuro-Oncology, 2013
- Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapyJournal of Neuro-Oncology, 2006